Celldex Therapeutics, Inc. — Form 8-K
Filed July 15, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 12/100
What the filing says
Celldex filed Form 8-K on July 15, 2026 disclosing Item 5.02 events: departure of directors or certain officers and changes to compensatory arrangements. The filing provides no specific names, dollar amounts, dates of departure, or details of compensation changes in the text provided.
Why this rating
Filing is boilerplate disclosure with no concrete details disclosed. Without names, amounts, or material terms, cannot assess business impact.
Extracted items
- 5.02 exec change
- 9.01 exhibits
See more from July 15, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.